

Veloxis Pharmaceuticals A/S  
Amerika Plads 37  
DK-2100 Copenhagen Ø

By email

15 January 2020

**Major shareholder notification**

Pursuant to Section 38 of the Danish Capital Markets Act and Section 55 of the Danish Companies Act, Novo Nordisk Fonden, CVR no. 10 58 29 89, hereby notifies Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 (“Veloxis Pharmaceuticals”), on behalf of its wholly-owned subsidiary Novo Holdings A/S, CVR no. 24 25 76 30, that as of 15 January 2020, we hold 0 (zero) shares in Veloxis Pharmaceuticals, corresponding to 0 % of the total share capital and voting rights in Veloxis Pharmaceuticals, as a result of acceptance of and the decision by Asahi Kasei Pharma Denmark A/S to complete the conditional voluntary public offer by Asahi Kasei Pharma Denmark A/S published on 25 November 2019.

Prior to acceptance and completion of the conditional voluntary public offer, Novo Nordisk Fonden indirectly held a total of 708,629,942 shares of nominal value DKK 0.10 each, corresponding to approximately 40.7 % of the share capital and voting rights of Veloxis Pharmaceuticals.

Kind regards

Novo Nordisk Fonden and Novo Holdings A/S